What is Amneal Pharmaceuticals, Inc.'s specialty — SG&A?

Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — SG&A of $34.69M in Q1 2026.

How has Amneal Pharmaceuticals, Inc.'s specialty — SG&A changed year-over-year?

Amneal Pharmaceuticals, Inc.'s specialty — SG&A increased by 12.0% year-over-year, from $30.98M to $34.69M.

What does specialty — SG&A mean?

Encompasses the overhead costs associated with operating the specialty segment, including salesforce compensation, marketing, and general administrative support. This metric reflects the operational intensity and investment required to maintain and grow the segment's market presence.

Amneal Pharmaceuticals, Inc. AMRX Specialty — SG&A

Other segment segments

Affordable Medicines

$37.27M+9.9%

AvKARE

$16.68M+6.3%

Similar metrics at other companies

LKQSpecialty — Selling, general and administrative expenses

$84M+10.5%

MLMSpecialties — Selling General And Administrative Expense

$10M+100%

ESISpecialties — Selling, technical, general and administrative

$55.6M+7.1%

GTLSSpecialty Products — Selling, general and administrative expenses

$32.9M+8.2%

RPMSpecialty Products Group — Selling General And Administrative Expense

$54.4M+1.4%

KLACSpecialty Semiconductor Process — SG&A

$11.52M+10.6%

Other financials

Income statement

See full

Revenue$722.5M+3.9%

Gross profit$320.1M+25.1%

Operating income$141.8M+41.3%

Net income$62.3M+411%

EPS (diluted)$0.19+375%

Balance sheet

See full

Cash & equivalents$197.7M+234%

Total debt$2.6B+17.7%

Total equity-$45.4M+65.5%

Total assets$3.5B+5.2%

Cash flow

See full

Operating cash flow-$26.7M-461%

CapEx$8.2M-37.9%

Free cash flow-$34.9M-507%

Valuation

See full

Market cap$5.17B+51.0%

Enterprise value$7.55B+33.4%

P/E42.4×—

P/S1.7×+0.5×

Profitability

See full

Gross margin38.7%+2.0pp

Operating margin14.3%+1.6pp

Net margin4%+3.6pp

FCF margin7.9%-1.0pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity127.9×+119×

Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — sg&a.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s specialty — SG&A?: Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — SG&A of $34.69M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — SG&A changed year-over-year?: Amneal Pharmaceuticals, Inc.'s specialty — SG&A increased by 12.0% year-over-year, from $30.98M to $34.69M.
What does specialty — SG&A mean?: Encompasses the overhead costs associated with operating the specialty segment, including salesforce compensation, marketing, and general administrative support. This metric reflects the operational intensity and investment required to maintain and grow the segment's market presence.